{"gene":"TNFRSF14","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1997,"finding":"HVEM (TNFRSF14) directly binds herpes simplex virus glycoprotein D (gD) via its cysteine-rich pseudorepeats, and this physical interaction mediates HSV entry into HVEM-expressing cells. The gD-HVEM complex has a 1:2 molar ratio (gD:HVEM) and approximately 113 kDa by gel filtration. gD binding is dependent on native gD conformation but independent of N-linked oligosaccharides.","method":"Recombinant protein binding assays (ELISA, gel filtration chromatography), competition studies, CHO cell infection assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro binding reconstitution with purified proteins, functional entry assay, replicated across multiple studies","pmids":["9223502"],"is_preprint":false},{"year":1997,"finding":"HVEM signals through TRAF2 and TRAF5 via a C-terminal 20-amino-acid intracellular domain, and overexpression of HVEM activates NF-κB. Co-expression with TRAF5 (but not TRAF2) results in synergistic NF-κB activation, suggesting distinct roles for each TRAF protein.","method":"Yeast two-hybrid, co-immunoprecipitation, NF-κB reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP and functional NF-κB assay with domain mapping","pmids":["9153189"],"is_preprint":false},{"year":2001,"finding":"X-ray crystal structure of HSV gD alone and in complex with the HVEM ectodomain revealed that gD contains a V-like immunoglobulin fold; the N-terminal hairpin of gD forms the receptor-binding segment and contacts HVEM CRD1, with a conformational change accompanying binding that may be part of the viral entry mechanism.","method":"X-ray crystallography","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of the gD-HVEM complex with functional implications","pmids":["11511370"],"is_preprint":false},{"year":2001,"finding":"The gD-binding domain of HVEM requires both CRD1 and CRD2 (residues 1–120); CRD1 alone or CRD2 alone is insufficient for gD binding. A monoclonal antibody recognizing a discontinuous epitope in CRD1 blocks gD binding, localizing the primary gD contact site to CRD1.","method":"Biosensor binding assays, ELISA, virus entry blocking with soluble HVEM truncation mutants and monoclonal antibodies","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal methods (biosensor, ELISA, antibody blocking) with defined domain mapping","pmids":["11119586"],"is_preprint":false},{"year":2002,"finding":"Structure-based mutagenesis of the gD-binding site on HVEM identified Y23 (CRD1) as a critical hot-spot residue that protrudes into a crevice on gD; a C37-C19 disulfide bond in CRD1 is essential for gD binding; CRD2 provides structural support for the CRD1 gD-binding site. HVEM-R75A showed enhanced gD binding.","method":"Alanine-scanning mutagenesis, gD binding assays, HSV entry assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis with functional entry assay validation","pmids":["12368332"],"is_preprint":false},{"year":2003,"finding":"Structure-based mutagenesis of gD defined three critical contact regions at the gD-HVEM interface: (i) residues forming an intermolecular β-sheet with HVEM, (ii) residues contacting HVEM-Y23, and (iii) one gD residue contacting HVEM CRD2. None of the gD mutations prevented nectin-1 binding, demonstrating that the gD binding surfaces for HVEM and nectin-1 are distinct.","method":"Site-directed mutagenesis, receptor binding assays, virus entry assay, cell-cell fusion assay","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 — structure-guided mutagenesis coupled with multiple functional assays","pmids":["12829851"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of the BTLA-HVEM complex at 2.8 Å resolution showed that BTLA binds the N-terminal CRD1 of HVEM using a surface that overlaps with the gD-binding site and employs a similar binding motif; BTLA adopts an Ig I-set fold; BTLA is monomeric in solution and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM further defined critical binding residues.","method":"X-ray crystallography, light scattering, alanine-scanning mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis plus biophysical stoichiometry measurement","pmids":["16169851"],"is_preprint":false},{"year":2000,"finding":"gD, LT-α, and LIGHT bind to distinct but overlapping sites on HVEM; peptide ligands differentially inhibit gD versus LT-α binding, and binding of one ligand to HVEM alters the receptor conformation, affecting binding of other ligands.","method":"Competitive binding assays with recombinant HVEM truncation mutants and peptide inhibitors, ELISA","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple binding competition assays with defined receptor fragments, single lab","pmids":["11164894"],"is_preprint":false},{"year":2009,"finding":"BTLA and HVEM form a cis heterodimeric complex on the surface of naive T cells that inhibits HVEM-dependent NF-κB RelA activation. The cis-BTLA ectodomain competitively blocks trans-engagement of BTLA and CD160 with HVEM. LIGHT can bind the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization in cis. HSV gD forms a cis-complex with HVEM but promotes NF-κB activation.","method":"Co-immunoprecipitation, NF-κB reporter assays, FACS-based binding assays, genetic deletion experiments, pharmacological disruption","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, functional NF-κB assays, genetic and pharmacological approaches in multiple orthogonal experiments","pmids":["19915044"],"is_preprint":false},{"year":2010,"finding":"HVEM engagement of BTLA produces inhibitory signals through SHP-1 and SHP-2 association; conversely, BTLA engagement of HVEM produces proinflammatory signals via NF-κB activation, establishing a bidirectional signaling system between the TNFR and Ig superfamilies.","method":"Biochemical signaling assays, co-immunoprecipitation (as reviewed with reference to primary experimental findings)","journal":"Annual review of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — synthesis of experimental findings from multiple labs; SHP-1/SHP-2 recruitment established in primary studies cited","pmids":["20307212"],"is_preprint":false},{"year":2008,"finding":"In a T cell transfer colitis model, HVEM expressed by radioresistant innate immune cells (not donor T cells) interacts with BTLA to prevent intestinal inflammation. Loss of HVEM in Rag−/− recipients dramatically accelerated colitis, demonstrating an anti-inflammatory role for HVEM-BTLA signaling in the gut microenvironment.","method":"T cell transfer colitis model with HVEM-deficient mice, bone marrow chimeras, in vivo genetic epistasis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular phenotype and epistasis, multiple experimental conditions","pmids":["18519647"],"is_preprint":false},{"year":2008,"finding":"HVEM-BTLA signaling provides an inhibitory checkpoint for dendritic cell homeostasis in lymphoid tissue. HVEM- or BTLA-deficient mice have overpopulated CD8α− DC subsets with a specific growth advantage; both DC-intrinsic and microenvironment expression are required. The LTβR pathway provides positive growth signals that are counter-regulated by HVEM-BTLA.","method":"Competitive bone marrow chimeric mice, flow cytometry of DC subsets, LTβR agonist antibody treatment, genetic KO","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — competitive repopulation assays and genetic KO with defined cellular phenotype","pmids":["18097025"],"is_preprint":false},{"year":2011,"finding":"HVEM promotes the persistence of memory T helper cells (Th1 and Th2) by activating PKB/Akt survival signaling. HVEM-deficient memory CD4 T cells display reduced Akt activity and fail to persist after antigen rechallenge; constitutively active Akt rescues their survival. LIGHT on T cells recapitulates the HVEM effect, suggesting T cell-to-T cell LIGHT-HVEM interactions maintain memory pools.","method":"Antigen-specific memory T cell transfer, intracellular signaling assays (Akt phosphorylation), constitutively active Akt rescue, HVEM-KO and LIGHT-KO mice","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with mechanistic rescue by constitutively active Akt, multiple T cell subsets tested","pmids":["21402741"],"is_preprint":false},{"year":2016,"finding":"Loss of HVEM (TNFRSF14) in germinal center B cells leads to cell-autonomous B cell proliferation and drives GC lymphoma development in vivo. HVEM-deficient B cells also induce a tumor-supportive microenvironment with increased TFH recruitment. Disruption of HVEM-BTLA inhibitory cell-cell interactions underlies these effects. The HVEM ectodomain protein (solHVEM) binds BTLA and restores tumor suppression.","method":"In vivo mouse lymphoma model, HVEM-KO B cell adoptive transfer, solHVEM protein administration, CAR-T cell engineering","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with multiple mechanistic readouts and protein rescue experiment","pmids":["27693350"],"is_preprint":false},{"year":2019,"finding":"HVEM on B cells restrains T follicular helper cell help to germinal center B cells through the BTLA-SHP1 axis: BTLA on T cells recruits SHP1, reduces TCR signaling, and limits preformed CD40L mobilization to the immunological synapse. T cell BTLA deficiency cooperates with B cell Bcl-2 overexpression to drive GC B cell outgrowth, establishing BTLA as a cell-extrinsic suppressor of GC B cell lymphomagenesis.","method":"BTLA-deficient T cells, phosphatase (SHP1) signaling assays, imaging of CD40L at the immunological synapse, Bcl-2 transgenic mouse model, in vivo lymphomagenesis model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — defined mechanistic pathway (SHP1, CD40L mobilization) with genetic and in vivo validation","pmids":["31204070"],"is_preprint":false},{"year":2016,"finding":"TNFRSF14 (HVEM) expressed on mast cells is engaged by TNFSF14 (LIGHT), enhancing IgE-mediated mast cell signaling and mediator production. In mouse asthma models, TNFRSF14 blockade or genetic deletion of Tnfrsf14 reduces antigen-specific IgE/IgG1, airway hyperreactivity, inflammation, and remodelling. Engraftment of TNFRSF14-deficient mast cells into mast-cell-deficient mice confirmed that MC-expressed TNFRSF14 is required for multiple asthma features.","method":"MC-deficient mice reconstituted with TNFRSF14-KO or WT MCs, anti-TNFRSF14 neutralizing antibody, in vitro IgE-mediated signaling assays, in vivo asthma model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — cell-specific reconstitution experiment plus genetic KO plus antibody blockade with defined cellular and molecular phenotype","pmids":["27982078"],"is_preprint":false},{"year":2016,"finding":"BTLA expressed on DEC205+CD8+CD11c+ dendritic cells promotes induction of extrathymic Foxp3+ regulatory T cells. HVEM engagement on T cells upregulates CD5, which enables Foxp3 expression by allowing T cells to resist cytokine-driven effector differentiation. In the absence of BTLA/HVEM, T cells remain CD5lo and fail to express Foxp3.","method":"DC subset-specific BTLA expression analysis, HVEM-KO and BTLA-KO mice, Foxp3 reporter system, CD5 expression assays, tolerance induction experiments","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined mechanistic intermediate (CD5 upregulation), multiple orthogonal readouts","pmids":["27793593"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of CD160 bound to HVEM reveals that CD160 adopts a unique Ig fold variant and forms a 1:1 complex with HVEM using a binding interface similar to that of BTLA:HVEM, overlapping on the CRD1 surface of HVEM.","method":"X-ray crystallography, solution stoichiometry analysis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of CD160:HVEM complex with biophysical characterization","pmids":["31230945"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of HVEM with LIGHT and with BTLA/CD160 define distinct non-overlapping binding surfaces on HVEM: the TNF ligand LIGHT binds one face while BTLA and CD160 bind CRD1. A ternary HVEM-LIGHT-CD160 complex was determined showing simultaneous engagement. HVEM knockin mutant mice selectively recognizing TNF or Ig ligands demonstrated that LIGHT-HVEM interactions are specifically required for intestinal bacterial clearance, while Ig ligand (BTLA/CD160)-HVEM interactions specifically ameliorate liver inflammation.","method":"X-ray crystallography (ternary complex), site-directed mutagenesis, knockin mice with ligand-selective HVEM mutants, in vivo infection model, liver inflammation model","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — crystal structure including ternary complex, validated by in vivo knockin muteins with selective loss-of-function phenotypes","pmids":["34709351"],"is_preprint":false},{"year":2022,"finding":"Epithelial HVEM, stimulated by LIGHT, promotes survival of intraepithelial T cells (IETs) by upregulating epithelial synthesis of collagen IV (a basement membrane protein), which in turn engages β1 integrins on IETs. This HVEM→collagen IV→β1 integrin axis maintains IET number, patrolling movement, and protective responses to Salmonella enterica.","method":"HVEM-KO in intestinal epithelium, RNA-seq of organoids treated with HVEM ligands, intravital microscopy, β1 integrin KO T cells, Salmonella infection model","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches including organoid signaling, live imaging, conditional KO, and infection model","pmids":["35905286"],"is_preprint":false},{"year":2024,"finding":"BTLA on CAR T cells interacts in trans with HVEM expressed on regulatory T cells in the tumor microenvironment, leading to recruitment of tyrosine phosphatases SHP-1 and SHP-2 that inhibit CAR signaling. Deletion of BTLA in CAR T cells improves tumor control and persistence by enhancing CAR signaling and effector function.","method":"BTLA-KO in CAR T cells (CRISPR), co-culture with HVEM-expressing Tregs, phosphatase recruitment assays, in vivo lymphoma and solid tumor models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of phosphatase recruitment with genetic KO and in vivo validation","pmids":["38831106"],"is_preprint":false},{"year":2011,"finding":"HVEM activates a STAT3 signaling pathway in intestinal epithelial cells (in addition to NF-κB), with STAT3 regulating genes important for host defense and influencing differentiation of Th17 cells and innate lymphoid cells.","method":"Signaling assays in epithelial cells, HVEM stimulation experiments (as described in primary studies referenced in the review)","journal":"Gut microbes","confidence":"Medium","confidence_rationale":"Tier 2 — signaling pathway identification, but described in a mini-review referencing primary data from a single lab","pmids":["23333859"],"is_preprint":false},{"year":2013,"finding":"HSV-1 latency-associated transcript (LAT) upregulates HVEM expression in latently infected neurons, and HVEM-deficient mice show significantly reduced HSV-1 latency and reactivation. Two LAT small noncoding RNAs bind the HVEM promoter, proposing a mechanism whereby LAT increases HVEM expression to promote neuronal survival and immune evasion during latency.","method":"Hvem−/− mouse latency model, in vitro LAT expression with HVEM promoter assays, LAT noncoding RNA binding studies","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO model with latency phenotype plus mechanistic promoter binding evidence, single lab","pmids":["24307582"],"is_preprint":false},{"year":2016,"finding":"SALM5 (a neuron-specific synaptic adhesion molecule) interacts with HVEM as a functional receptor to suppress CNS inflammation. Anti-SALM5 antibody promoted inflammation in the CNS and aggravated experimental autoimmune encephalomyelitis symptoms, identifying HVEM as a mediator of SALM5-dependent CNS immune privilege.","method":"Pulldown/interaction assay, anti-SALM5 monoclonal antibody treatment, EAE mouse model, LPS-induced CNS inflammation","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2/3 — novel HVEM binding partner identified with functional in vivo evidence, single lab","pmids":["27152329"],"is_preprint":false},{"year":2018,"finding":"HVEM signaling in ILC3 innate lymphoid cells, stimulated by LIGHT, drives protective IFN-γ secretion during Yersinia enterocolitica oral infection. Mice with HVEM-deficient ILC3 show reduced IFN-γ, higher bacterial burdens, and increased mortality; adoptive transfer of WT but not IFN-γ-deficient ILC3 restores protection.","method":"Conditional HVEM KO in ILC3, adoptive transfer of IFN-γ-KO ILC3, Yersinia oral infection model","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 — cell-specific KO and adoptive transfer rescue experiment with defined mechanistic output (IFN-γ)","pmids":["30092201"],"is_preprint":false},{"year":2008,"finding":"HSV-1 gD interaction with HVEM (but not a HVEM-binding-incompetent gD mutant) activates NF-κB-dependent anti-apoptotic signaling in HVEM-expressing cells. Blocking gD-HVEM interaction with specific MAbs or using an HVEM-non-binding gD mutant abolishes protection against Fas-mediated apoptosis, demonstrating that NF-κB survival signaling requires gD-HVEM engagement.","method":"MAb blocking of gD-HVEM interaction, gD point mutants unable to bind HVEM, apoptosis assays in HVEM-expressing cells vs. control cells","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 2 — structure-guided loss-of-function (non-binding gD mutant and receptor-specific MAb) with functional apoptosis readout","pmids":["18723002"],"is_preprint":false},{"year":2022,"finding":"In T cell reporter systems, co-expression of LIGHT or CD160 (but not BTLA) with HVEM induces strong constitutive HVEM signaling. In the cis-BTLA:HVEM complex, BTLA-mediated inhibitory signaling is dominant and not impaired, while HVEM co-stimulation by trans-ligands is blocked. HVEM antibodies can simultaneously act as checkpoint inhibitors and co-stimulation agonists.","method":"T cell reporter systems, primary human T cell stimulation assays, co-expression experiments with HVEM and its ligands","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional reporter assays with primary cells, single lab","pmids":["36081508"],"is_preprint":false}],"current_model":"TNFRSF14/HVEM is a bidirectional signaling receptor that engages structurally distinct ligand classes on separate surfaces: TNF-family members LIGHT and LTα bind one face (activating NF-κB and STAT3 pro-inflammatory/survival pathways via TRAF2/TRAF5), while Ig-superfamily members BTLA and CD160 bind the N-terminal CRD1 (at the same site as HSV gD) to deliver inhibitory signals through SHP-1/SHP-2 recruitment; on naive T cells, HVEM and BTLA form a cis heterodimer that blocks trans-activation and maintains the inhibitory tone, whereas disruption of this complex or loss of HVEM releases B and T cell activation, promotes germinal center responses, and in epithelial cells drives collagen IV production that maintains intraepithelial T cell survival via β1 integrins."},"narrative":{"teleology":[{"year":1997,"claim":"Identification of HVEM as the entry receptor for HSV via direct binding of glycoprotein D established that a TNF receptor family member could serve as a viral receptor, opening investigation of its ligand repertoire.","evidence":"Recombinant protein binding assays, gel filtration, and CHO cell infection assays","pmids":["9223502"],"confidence":"High","gaps":["Physiological (non-viral) ligands were unknown","Signaling consequences of gD engagement were uncharacterized"]},{"year":1997,"claim":"Demonstration that HVEM signals through TRAF2 and TRAF5 to activate NF-κB revealed that HVEM functions as a classical TNFR-family signaling receptor, not merely a viral entry factor.","evidence":"Yeast two-hybrid, co-immunoprecipitation, NF-κB reporter assay with domain mapping","pmids":["9153189"],"confidence":"High","gaps":["Identity of endogenous activating ligands was unknown","Downstream transcriptional targets of HVEM-NF-κB not defined"]},{"year":2000,"claim":"Competitive binding studies showed that gD, LTα, and LIGHT occupy distinct but overlapping sites on HVEM, establishing that HVEM is a multi-ligand receptor capable of integrating different inputs.","evidence":"Competitive binding assays with recombinant HVEM truncation mutants and peptide inhibitors","pmids":["11164894"],"confidence":"Medium","gaps":["Structural basis for distinct binding faces not resolved","Functional consequence of simultaneous ligand engagement unknown"]},{"year":2001,"claim":"Crystal structures of gD alone and in complex with HVEM, combined with domain mapping, localized the gD contact to CRD1 and revealed a conformational change mechanism relevant to viral entry.","evidence":"X-ray crystallography at atomic resolution; biosensor binding and antibody blocking with HVEM truncation mutants","pmids":["11511370","11119586","12368332"],"confidence":"High","gaps":["Whether CRD1 also served as the binding site for endogenous Ig-superfamily ligands was unknown","Structural basis for LIGHT/LTα binding not yet determined"]},{"year":2005,"claim":"The crystal structure of the BTLA–HVEM complex revealed that an Ig-superfamily inhibitory receptor binds CRD1 of a TNF receptor, using a surface overlapping with gD, establishing an unprecedented cross-superfamily signaling paradigm.","evidence":"X-ray crystallography at 2.8 Å, light scattering, alanine-scanning mutagenesis","pmids":["16169851"],"confidence":"High","gaps":["How BTLA inhibitory signaling was transduced upon HVEM engagement was incompletely defined","Whether CD160 shared this binding mode was unknown"]},{"year":2008,"claim":"In vivo genetic studies demonstrated that HVEM–BTLA signaling functions as an inhibitory checkpoint controlling dendritic cell homeostasis and preventing intestinal inflammation, establishing HVEM's physiological role as a negative regulator beyond T cells.","evidence":"HVEM-KO and BTLA-KO mice, competitive bone marrow chimeras, T cell transfer colitis model","pmids":["18519647","18097025"],"confidence":"High","gaps":["Cell-type-specific contributions of HVEM in epithelium vs. immune compartment were not separated","STAT3 pathway involvement not yet established"]},{"year":2008,"claim":"gD–HVEM engagement was shown to activate NF-κB-dependent anti-apoptotic signaling, demonstrating that HSV exploits HVEM survival signaling during infection.","evidence":"Blocking MAbs, non-binding gD mutants, Fas-mediated apoptosis assays in HVEM-expressing cells","pmids":["18723002"],"confidence":"High","gaps":["Whether this survival pathway operates during latency was unresolved","Downstream NF-κB target genes not identified"]},{"year":2009,"claim":"Discovery that BTLA and HVEM form a cis-complex on naive T cells that blocks trans-activation resolved how inhibitory tone is maintained at steady state and explained why HVEM loss leads to immune activation.","evidence":"Co-immunoprecipitation, NF-κB reporter assays, FACS-based binding, genetic deletion in T cells","pmids":["19915044"],"confidence":"High","gaps":["Molecular mechanism preventing HVEM oligomerization in cis not fully resolved","How the cis-complex is disrupted during activation was not defined"]},{"year":2010,"claim":"Characterization of HVEM–BTLA as a bidirectional signaling axis — BTLA delivers SHP-1/SHP-2 inhibitory signals while HVEM receives NF-κB-activating signals — unified the co-stimulatory and co-inhibitory functions into a single molecular interaction.","evidence":"Biochemical signaling assays, co-immunoprecipitation (synthesized from multiple primary studies)","pmids":["20307212"],"confidence":"Medium","gaps":["Relative contribution of SHP-1 vs. SHP-2 in different cell types not delineated","Quantitative signaling thresholds not established"]},{"year":2011,"claim":"HVEM was shown to promote memory T cell persistence through Akt survival signaling triggered by LIGHT, identifying a non-redundant role for HVEM in adaptive immune memory maintenance.","evidence":"HVEM-KO and LIGHT-KO memory CD4 T cell transfers, Akt phosphorylation assays, constitutively active Akt rescue","pmids":["21402741"],"confidence":"High","gaps":["Whether Akt activation is TRAF-dependent or uses a distinct adaptor was unknown","Role in CD8 memory maintenance not fully tested"]},{"year":2013,"claim":"HSV-1 latency-associated transcript was found to upregulate HVEM expression in neurons, and HVEM-deficient mice showed reduced latency and reactivation, revealing that HSV co-opts HVEM signaling for long-term persistence.","evidence":"Hvem−/− mouse latency model, LAT noncoding RNA promoter-binding studies","pmids":["24307582"],"confidence":"Medium","gaps":["LAT–HVEM promoter interaction not validated by independent lab","Downstream neuronal survival pathway not fully delineated"]},{"year":2016,"claim":"Loss of HVEM in germinal center B cells was shown to drive cell-autonomous proliferation and lymphomagenesis; soluble HVEM ectodomain restored BTLA-dependent tumor suppression, establishing HVEM as a tumor suppressor in GC B cell lymphoma.","evidence":"In vivo mouse lymphoma model, HVEM-KO B cell adoptive transfer, solHVEM protein rescue, CAR-T engineering","pmids":["27693350"],"confidence":"High","gaps":["Whether solHVEM achieves durable suppression in established tumors was not tested","Downstream transcriptional program in HVEM-deficient GC B cells not characterized"]},{"year":2016,"claim":"Multiple tissue-specific roles of HVEM were simultaneously uncovered: BTLA-expressing DCs use HVEM engagement to upregulate CD5 and induce Foxp3+ regulatory T cells; HVEM on mast cells mediates LIGHT-driven IgE signaling and asthma pathology; and SALM5 was identified as a neuronal HVEM ligand suppressing CNS inflammation.","evidence":"DC subset analysis in HVEM/BTLA-KO mice with Foxp3 reporters; mast cell reconstitution in MC-deficient mice with TNFRSF14-KO MCs; pulldown and EAE model for SALM5","pmids":["27793593","27982078","27152329"],"confidence":"High","gaps":["SALM5–HVEM interaction awaits structural validation and independent confirmation","Mast cell HVEM signaling intermediates beyond NF-κB not defined","Whether CD5 upregulation is a direct HVEM transcriptional target unclear"]},{"year":2018,"claim":"HVEM signaling in ILC3 was shown to drive protective IFN-γ production during enteric bacterial infection, extending HVEM's mucosal defense role to innate lymphoid cells.","evidence":"Conditional HVEM KO in ILC3, adoptive transfer of IFN-γ-KO ILC3, Yersinia oral infection model","pmids":["30092201"],"confidence":"High","gaps":["Signaling intermediates linking HVEM to IFN-γ transcription in ILC3 not identified","Whether LIGHT is the sole activating ligand for ILC3-HVEM in vivo not confirmed"]},{"year":2019,"claim":"Crystal structure of CD160–HVEM confirmed that CD160 shares the CRD1 binding surface with BTLA, and mechanistic studies showed that BTLA on T cells recruits SHP1 to suppress TCR signaling and CD40L mobilization, establishing the molecular basis for HVEM-dependent GC B cell lymphoma suppression.","evidence":"X-ray crystallography of CD160:HVEM; BTLA-KO T cells with SHP1 signaling and CD40L imaging in Bcl-2 transgenic lymphomagenesis model","pmids":["31230945","31204070"],"confidence":"High","gaps":["Whether CD160 delivers inhibitory or activating signals through HVEM in vivo not fully resolved","Relative contributions of SHP1 vs SHP2 to BTLA-mediated suppression of TCR signaling not quantified"]},{"year":2021,"claim":"Crystal structures of HVEM with LIGHT and a ternary HVEM–LIGHT–CD160 complex definitively showed that TNF and Ig ligands bind non-overlapping surfaces, enabling simultaneous engagement; ligand-selective HVEM knockin mice proved that LIGHT–HVEM drives intestinal bacterial clearance while BTLA/CD160–HVEM ameliorates liver inflammation.","evidence":"X-ray crystallography including ternary complex, knockin mice with ligand-selective HVEM mutations, infection and inflammation models","pmids":["34709351"],"confidence":"High","gaps":["How simultaneous ternary engagement alters net signaling output quantitatively is unclear","Whether the ternary complex forms physiologically in specific tissues not demonstrated"]},{"year":2022,"claim":"Epithelial HVEM was shown to sustain intraepithelial T cells by a previously unrecognized mechanism: LIGHT-HVEM signaling induces epithelial collagen IV, which engages β1 integrins on IETs to promote survival and motility.","evidence":"Epithelial HVEM conditional KO, organoid RNA-seq, intravital microscopy, β1 integrin KO T cells, Salmonella infection model","pmids":["35905286"],"confidence":"High","gaps":["Signaling pathway from HVEM to collagen IV transcription in epithelial cells not fully mapped","Whether this axis operates outside the gut epithelium unknown"]},{"year":2024,"claim":"HVEM on regulatory T cells in the tumor microenvironment was identified as a functional ligand that engages BTLA on CAR T cells, recruiting SHP-1/SHP-2 to suppress CAR signaling; BTLA deletion in CAR T cells enhanced anti-tumor efficacy, validating the HVEM–BTLA axis as a therapeutic target in adoptive cell therapy.","evidence":"CRISPR BTLA-KO in CAR T cells, co-culture with HVEM+ Tregs, phosphatase recruitment assays, in vivo lymphoma and solid tumor models","pmids":["38831106"],"confidence":"High","gaps":["Whether HVEM on other TME cell types contributes to CAR T suppression not addressed","Long-term safety of BTLA-deleted CAR T cells not evaluated"]},{"year":null,"claim":"Key open questions include the signaling intermediates linking HVEM to STAT3 and Akt in different cell types, how the cis-BTLA:HVEM complex is physiologically disrupted during activation, the structural basis for SALM5–HVEM interaction, and whether ternary HVEM–LIGHT–CD160 complexes form in vivo and alter net signaling output.","evidence":"","pmids":[],"confidence":"Low","gaps":["Adaptor proteins linking HVEM to Akt not identified","Mechanism of cis-to-trans switch during T cell activation undefined","SALM5–HVEM structural and biophysical characterization absent","Physiological relevance of ternary complex in specific tissues not demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,7,8,9,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,9,13,14,26]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,8,17,26]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,13,14,15,16,20,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,8,9,12,21,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,13,22]}],"complexes":["cis-BTLA:HVEM complex"],"partners":["BTLA","CD160","TNFSF14","LTA","TRAF2","TRAF5","PTPN6","PTPN11"],"other_free_text":[]},"mechanistic_narrative":"TNFRSF14 (HVEM) is a bidirectional signaling hub at the interface of the TNF receptor and immunoglobulin superfamilies, integrating pro-inflammatory, survival, and inhibitory signals to regulate lymphocyte activation, memory, tolerance, and mucosal immunity. Its CRD1 domain engages Ig-superfamily ligands BTLA and CD160 (and HSV glycoprotein D) to deliver inhibitory signals via SHP-1/SHP-2 recruitment on the opposing cell, while a distinct surface binds TNF-family ligands LIGHT and LTα to activate NF-κB (through TRAF2/TRAF5), STAT3, and Akt survival pathways [PMID:9153189, PMID:34709351, PMID:20307212, PMID:21402741]. On naive T cells, HVEM and BTLA form a cis-complex that competitively blocks trans-engagement, maintaining inhibitory tone; disruption of this complex releases B and T cell activation and, in germinal center B cells, promotes lymphomagenesis driven by unchecked TFH help [PMID:19915044, PMID:27693350, PMID:31204070]. In mucosal tissues, LIGHT–HVEM signaling on ILC3 drives protective IFN-γ during enteric infection, while epithelial HVEM stimulates collagen IV production that sustains intraepithelial T cell survival through β1 integrins [PMID:30092201, PMID:35905286]."},"prefetch_data":{"uniprot":{"accession":"Q92956","full_name":"Tumor necrosis factor receptor superfamily member 14","aliases":["Herpes virus entry mediator A","Herpesvirus entry mediator A","HveA","Tumor necrosis factor receptor-like 2","TR2"],"length_aa":283,"mass_kda":30.4,"function":"Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network (PubMed:10754304, PubMed:18193050, PubMed:23761635, PubMed:9462508). Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation (PubMed:19915044, PubMed:9153189, PubMed:9162022). Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions (PubMed:10754304). Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response (PubMed:23761635). In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity). Upon binding to CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with BTLA (By similarity) (PubMed:19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (By similarity) (PubMed:19915044) (Microbial infection) Acts as a receptor for Herpes simplex virus 1/HHV-1 (Microbial infection) Acts as a receptor for Herpes simplex virus 2/HHV-2","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q92956/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF14","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF14","total_profiled":1310},"omim":[{"mim_id":"607925","title":"B- AND T-LYMPHOCYTE ATTENUATOR; BTLA","url":"https://www.omim.org/entry/607925"},{"mim_id":"605341","title":"PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, ALPHA; PILRA","url":"https://www.omim.org/entry/605341"},{"mim_id":"605027","title":"LYMPHOMA, NON-HODGKIN, FAMILIAL","url":"https://www.omim.org/entry/605027"},{"mim_id":"604520","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 14; TNFSF14","url":"https://www.omim.org/entry/604520"},{"mim_id":"602746","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14","url":"https://www.omim.org/entry/602746"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF14"},"hgnc":{"alias_symbol":["HVEM","ATAR","TR2","LIGHTR","HVEA","CD270"],"prev_symbol":[]},"alphafold":{"accession":"Q92956","domains":[{"cath_id":"2.10.50.10","chopping":"39-95","consensus_level":"medium","plddt":95.7056,"start":39,"end":95},{"cath_id":"-","chopping":"147-179","consensus_level":"medium","plddt":95.3718,"start":147,"end":179}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92956","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92956-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92956-F1-predicted_aligned_error_v6.png","plddt_mean":79.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF14","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF14"},"sequence":{"accession":"Q92956","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92956.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92956/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92956"}},"corpus_meta":[{"pmid":"11511370","id":"PMC_11511370","title":"Herpes simplex virus glycoprotein D bound to the human receptor HveA.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11511370","citation_count":319,"is_preprint":false},{"pmid":"16932752","id":"PMC_16932752","title":"Balancing co-stimulation and inhibition with BTLA and HVEM.","date":"2006","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16932752","citation_count":258,"is_preprint":false},{"pmid":"9223502","id":"PMC_9223502","title":"Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9223502","citation_count":254,"is_preprint":false},{"pmid":"19426226","id":"PMC_19426226","title":"The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426226","citation_count":247,"is_preprint":false},{"pmid":"27693350","id":"PMC_27693350","title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27693350","citation_count":207,"is_preprint":false},{"pmid":"7929568","id":"PMC_7929568","title":"HVEM tomography of the trans-Golgi network: structural insights and identification of a lace-like vesicle coat.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7929568","citation_count":203,"is_preprint":false},{"pmid":"22017438","id":"PMC_22017438","title":"The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017438","citation_count":197,"is_preprint":false},{"pmid":"16319225","id":"PMC_16319225","title":"Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16319225","citation_count":189,"is_preprint":false},{"pmid":"20307212","id":"PMC_20307212","title":"Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.","date":"2010","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20307212","citation_count":187,"is_preprint":false},{"pmid":"9153189","id":"PMC_9153189","title":"ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9153189","citation_count":148,"is_preprint":false},{"pmid":"16169851","id":"PMC_16169851","title":"Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169851","citation_count":140,"is_preprint":false},{"pmid":"19915044","id":"PMC_19915044","title":"T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19915044","citation_count":131,"is_preprint":false},{"pmid":"27793593","id":"PMC_27793593","title":"Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27793593","citation_count":121,"is_preprint":false},{"pmid":"18519647","id":"PMC_18519647","title":"A crucial role for HVEM and BTLA in preventing intestinal inflammation.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18519647","citation_count":115,"is_preprint":false},{"pmid":"9774688","id":"PMC_9774688","title":"Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9774688","citation_count":113,"is_preprint":false},{"pmid":"12787566","id":"PMC_12787566","title":"LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787566","citation_count":108,"is_preprint":false},{"pmid":"21670149","id":"PMC_21670149","title":"Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21670149","citation_count":106,"is_preprint":false},{"pmid":"27257180","id":"PMC_27257180","title":"Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27257180","citation_count":104,"is_preprint":false},{"pmid":"12829851","id":"PMC_12829851","title":"Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12829851","citation_count":103,"is_preprint":false},{"pmid":"12093744","id":"PMC_12093744","title":"An embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12093744","citation_count":98,"is_preprint":false},{"pmid":"12915538","id":"PMC_12915538","title":"Mutations in the N termini of herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion receptors HVEM, nectin-2, and 3-O-sulfated heparan sulfate but not with nectin-1.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12915538","citation_count":98,"is_preprint":false},{"pmid":"2597158","id":"PMC_2597158","title":"Molecular cloning of new human TR2 receptors: a class of steroid receptor with multiple ligand-binding domains.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2597158","citation_count":94,"is_preprint":false},{"pmid":"21106644","id":"PMC_21106644","title":"Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/21106644","citation_count":92,"is_preprint":false},{"pmid":"12368332","id":"PMC_12368332","title":"Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).","date":"2002","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12368332","citation_count":90,"is_preprint":false},{"pmid":"11901205","id":"PMC_11901205","title":"Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11901205","citation_count":90,"is_preprint":false},{"pmid":"31204070","id":"PMC_31204070","title":"The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31204070","citation_count":88,"is_preprint":false},{"pmid":"12615731","id":"PMC_12615731","title":"Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12615731","citation_count":87,"is_preprint":false},{"pmid":"12361719","id":"PMC_12361719","title":"Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily.","date":"2002","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12361719","citation_count":79,"is_preprint":false},{"pmid":"18097025","id":"PMC_18097025","title":"The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18097025","citation_count":77,"is_preprint":false},{"pmid":"9621040","id":"PMC_9621040","title":"HveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion.","date":"1998","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9621040","citation_count":71,"is_preprint":false},{"pmid":"30984188","id":"PMC_30984188","title":"BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30984188","citation_count":70,"is_preprint":false},{"pmid":"37649037","id":"PMC_37649037","title":"Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37649037","citation_count":69,"is_preprint":false},{"pmid":"21402741","id":"PMC_21402741","title":"Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T helper memory cell populations.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21402741","citation_count":62,"is_preprint":false},{"pmid":"23439006","id":"PMC_23439006","title":"Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23439006","citation_count":60,"is_preprint":false},{"pmid":"16275888","id":"PMC_16275888","title":"LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16275888","citation_count":58,"is_preprint":false},{"pmid":"17179227","id":"PMC_17179227","title":"Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17179227","citation_count":58,"is_preprint":false},{"pmid":"8530418","id":"PMC_8530418","title":"Multiple functions of the TR2-11 orphan receptor in modulating activation of two key cis-acting elements involved in the retinoic acid signal transduction system.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8530418","citation_count":57,"is_preprint":false},{"pmid":"15922943","id":"PMC_15922943","title":"The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15922943","citation_count":56,"is_preprint":false},{"pmid":"34532285","id":"PMC_34532285","title":"BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34532285","citation_count":55,"is_preprint":false},{"pmid":"34234757","id":"PMC_34234757","title":"Isolation and Characterization of a Novel Salmonella Phage vB_SalP_TR2.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34234757","citation_count":55,"is_preprint":false},{"pmid":"7890658","id":"PMC_7890658","title":"Identification of human TR2 orphan receptor response element in the transcriptional initiation site of the simian virus 40 major late promoter.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7890658","citation_count":54,"is_preprint":false},{"pmid":"26965583","id":"PMC_26965583","title":"Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.","date":"2016","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/26965583","citation_count":53,"is_preprint":false},{"pmid":"23445872","id":"PMC_23445872","title":"Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.","date":"2013","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/23445872","citation_count":53,"is_preprint":false},{"pmid":"24205056","id":"PMC_24205056","title":"CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24205056","citation_count":50,"is_preprint":false},{"pmid":"30092201","id":"PMC_30092201","title":"LIGHT-HVEM Signaling in Innate Lymphoid Cell Subsets Protects Against Enteric Bacterial Infection.","date":"2018","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/30092201","citation_count":49,"is_preprint":false},{"pmid":"11119586","id":"PMC_11119586","title":"Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11119586","citation_count":47,"is_preprint":false},{"pmid":"19760072","id":"PMC_19760072","title":"Targeting the LIGHT-HVEM pathway.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760072","citation_count":45,"is_preprint":false},{"pmid":"17974920","id":"PMC_17974920","title":"The TR2 and TR4 orphan nuclear receptors repress Gata1 transcription.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17974920","citation_count":45,"is_preprint":false},{"pmid":"15917993","id":"PMC_15917993","title":"Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.","date":"2005","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/15917993","citation_count":45,"is_preprint":false},{"pmid":"24307582","id":"PMC_24307582","title":"Interactions between herpesvirus entry mediator (TNFRSF14) and latency-associated transcript during herpes simplex virus 1 latency.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24307582","citation_count":44,"is_preprint":false},{"pmid":"30885361","id":"PMC_30885361","title":"HVEM network signaling in cancer.","date":"2019","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30885361","citation_count":44,"is_preprint":false},{"pmid":"21220749","id":"PMC_21220749","title":"Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21220749","citation_count":44,"is_preprint":false},{"pmid":"8241550","id":"PMC_8241550","title":"HVEM ultrastructural analysis of mouse fungiform taste buds, cell types, and associated synapses.","date":"1993","source":"Microscopy research and technique","url":"https://pubmed.ncbi.nlm.nih.gov/8241550","citation_count":43,"is_preprint":false},{"pmid":"30718814","id":"PMC_30718814","title":"Mechanism of regulation and neutralization of the AtaR-AtaT toxin-antitoxin system.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30718814","citation_count":41,"is_preprint":false},{"pmid":"2760687","id":"PMC_2760687","title":"Three-dimensional morphometrical study of dendritic spines of the granule cell in the rat dentate gyrus with HVEM stereo images.","date":"1989","source":"Journal of electron microscopy technique","url":"https://pubmed.ncbi.nlm.nih.gov/2760687","citation_count":41,"is_preprint":false},{"pmid":"33917094","id":"PMC_33917094","title":"BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33917094","citation_count":40,"is_preprint":false},{"pmid":"30429008","id":"PMC_30429008","title":"The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.","date":"2018","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/30429008","citation_count":40,"is_preprint":false},{"pmid":"27152329","id":"PMC_27152329","title":"Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM.","date":"2016","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/27152329","citation_count":40,"is_preprint":false},{"pmid":"18723002","id":"PMC_18723002","title":"Involvement of gD/HVEM interaction in NF-kB-dependent inhibition of apoptosis by HSV-1 gD.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18723002","citation_count":40,"is_preprint":false},{"pmid":"17145304","id":"PMC_17145304","title":"BTLA and HVEM cross talk regulates inhibition and costimulation.","date":"2006","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17145304","citation_count":39,"is_preprint":false},{"pmid":"30116751","id":"PMC_30116751","title":"Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30116751","citation_count":38,"is_preprint":false},{"pmid":"28612127","id":"PMC_28612127","title":"Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer.","date":"2017","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28612127","citation_count":37,"is_preprint":false},{"pmid":"38831106","id":"PMC_38831106","title":"The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38831106","citation_count":36,"is_preprint":false},{"pmid":"36081508","id":"PMC_36081508","title":"BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36081508","citation_count":36,"is_preprint":false},{"pmid":"11164894","id":"PMC_11164894","title":"The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11164894","citation_count":36,"is_preprint":false},{"pmid":"31230945","id":"PMC_31230945","title":"Structural Basis of CD160:HVEM Recognition.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31230945","citation_count":35,"is_preprint":false},{"pmid":"28527578","id":"PMC_28527578","title":"TR2 and TR4 Orphan Nuclear Receptors: An Overview.","date":"2017","source":"Current topics in developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28527578","citation_count":35,"is_preprint":false},{"pmid":"21236258","id":"PMC_21236258","title":"LIGHT/TNFSF14 enhances adipose tissue inflammatory responses through its interaction with HVEM.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21236258","citation_count":35,"is_preprint":false},{"pmid":"14562115","id":"PMC_14562115","title":"Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.","date":"2003","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/14562115","citation_count":35,"is_preprint":false},{"pmid":"27982078","id":"PMC_27982078","title":"A TNFRSF14-FcɛRI-mast cell pathway contributes to development of multiple features of asthma pathology in mice.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27982078","citation_count":33,"is_preprint":false},{"pmid":"19495760","id":"PMC_19495760","title":"Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners.","date":"2009","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19495760","citation_count":33,"is_preprint":false},{"pmid":"22993162","id":"PMC_22993162","title":"A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22993162","citation_count":33,"is_preprint":false},{"pmid":"19129446","id":"PMC_19129446","title":"Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition.","date":"2009","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/19129446","citation_count":32,"is_preprint":false},{"pmid":"25595777","id":"PMC_25595777","title":"Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25595777","citation_count":31,"is_preprint":false},{"pmid":"22297640","id":"PMC_22297640","title":"Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22297640","citation_count":30,"is_preprint":false},{"pmid":"27103745","id":"PMC_27103745","title":"TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27103745","citation_count":29,"is_preprint":false},{"pmid":"9694834","id":"PMC_9694834","title":"A bidirectional regulation between the TR2/TR4 orphan receptors (TR2/TR4) and the ciliary neurotrophic factor (CNTF) signaling pathway.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9694834","citation_count":29,"is_preprint":false},{"pmid":"28594868","id":"PMC_28594868","title":"Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28594868","citation_count":28,"is_preprint":false},{"pmid":"11976496","id":"PMC_11976496","title":"Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA.","date":"2002","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/11976496","citation_count":28,"is_preprint":false},{"pmid":"11463856","id":"PMC_11463856","title":"The orphan nuclear receptor TR2 interacts directly with both class I and class II histone deacetylases.","date":"2001","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11463856","citation_count":27,"is_preprint":false},{"pmid":"34208480","id":"PMC_34208480","title":"Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34208480","citation_count":27,"is_preprint":false},{"pmid":"17893608","id":"PMC_17893608","title":"Blockade of LIGHT/HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance.","date":"2007","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/17893608","citation_count":27,"is_preprint":false},{"pmid":"28701403","id":"PMC_28701403","title":"Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28701403","citation_count":26,"is_preprint":false},{"pmid":"24851095","id":"PMC_24851095","title":"HVEM is a TNF Receptor with Multiple Regulatory Roles in the Mucosal Immune System.","date":"2014","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/24851095","citation_count":26,"is_preprint":false},{"pmid":"23333859","id":"PMC_23333859","title":"HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.","date":"2013","source":"Gut microbes","url":"https://pubmed.ncbi.nlm.nih.gov/23333859","citation_count":26,"is_preprint":false},{"pmid":"19234349","id":"PMC_19234349","title":"Role of nectin-1, HVEM, and PILR-alpha in HSV-2 entry into human retinal pigment epithelial cells.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19234349","citation_count":26,"is_preprint":false},{"pmid":"34478526","id":"PMC_34478526","title":"Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34478526","citation_count":25,"is_preprint":false},{"pmid":"17389641","id":"PMC_17389641","title":"Orphan nuclear receptor TR2, a mediator of preadipocyte proliferation, is differentially regulated by RA through exchange of coactivator PCAF with corepressor RIP140 on a platform molecule GRIP1.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17389641","citation_count":25,"is_preprint":false},{"pmid":"15925518","id":"PMC_15925518","title":"Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling.","date":"2005","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/15925518","citation_count":25,"is_preprint":false},{"pmid":"18840367","id":"PMC_18840367","title":"An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.","date":"2008","source":"Clinical therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18840367","citation_count":25,"is_preprint":false},{"pmid":"3023604","id":"PMC_3023604","title":"Initiation of swimming activity by trigger neurons in the leech subesophageal ganglion. III. Sensory inputs to Tr1 and Tr2.","date":"1986","source":"Journal of comparative physiology. A, Sensory, neural, and behavioral physiology","url":"https://pubmed.ncbi.nlm.nih.gov/3023604","citation_count":25,"is_preprint":false},{"pmid":"35905286","id":"PMC_35905286","title":"Epithelial HVEM maintains intraepithelial T cell survival and contributes to host protection.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35905286","citation_count":24,"is_preprint":false},{"pmid":"34709351","id":"PMC_34709351","title":"HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34709351","citation_count":24,"is_preprint":false},{"pmid":"12949936","id":"PMC_12949936","title":"TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.","date":"2003","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/12949936","citation_count":24,"is_preprint":false},{"pmid":"27458100","id":"PMC_27458100","title":"Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.","date":"2016","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/27458100","citation_count":24,"is_preprint":false},{"pmid":"29858685","id":"PMC_29858685","title":"Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.","date":"2018","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29858685","citation_count":23,"is_preprint":false},{"pmid":"31963646","id":"PMC_31963646","title":"Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31963646","citation_count":23,"is_preprint":false},{"pmid":"26650888","id":"PMC_26650888","title":"Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.","date":"2015","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26650888","citation_count":23,"is_preprint":false},{"pmid":"9660764","id":"PMC_9660764","title":"Mechanisms of the mouse orphan nuclear receptor TR2-11-mediated gene suppression.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9660764","citation_count":23,"is_preprint":false},{"pmid":"10366573","id":"PMC_10366573","title":"Functional characterization of the HveA homolog specified by African green monkey kidney cells with a herpes simplex virus expressing the green fluorescence protein.","date":"1999","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/10366573","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48277,"output_tokens":6608,"usd":0.121976},"stage2":{"model":"claude-opus-4-6","input_tokens":10355,"output_tokens":4294,"usd":0.238687},"total_usd":0.360663,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"HVEM (TNFRSF14) directly binds herpes simplex virus glycoprotein D (gD) via its cysteine-rich pseudorepeats, and this physical interaction mediates HSV entry into HVEM-expressing cells. The gD-HVEM complex has a 1:2 molar ratio (gD:HVEM) and approximately 113 kDa by gel filtration. gD binding is dependent on native gD conformation but independent of N-linked oligosaccharides.\",\n      \"method\": \"Recombinant protein binding assays (ELISA, gel filtration chromatography), competition studies, CHO cell infection assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro binding reconstitution with purified proteins, functional entry assay, replicated across multiple studies\",\n      \"pmids\": [\"9223502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"HVEM signals through TRAF2 and TRAF5 via a C-terminal 20-amino-acid intracellular domain, and overexpression of HVEM activates NF-κB. Co-expression with TRAF5 (but not TRAF2) results in synergistic NF-κB activation, suggesting distinct roles for each TRAF protein.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, NF-κB reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP and functional NF-κB assay with domain mapping\",\n      \"pmids\": [\"9153189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"X-ray crystal structure of HSV gD alone and in complex with the HVEM ectodomain revealed that gD contains a V-like immunoglobulin fold; the N-terminal hairpin of gD forms the receptor-binding segment and contacts HVEM CRD1, with a conformational change accompanying binding that may be part of the viral entry mechanism.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of the gD-HVEM complex with functional implications\",\n      \"pmids\": [\"11511370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The gD-binding domain of HVEM requires both CRD1 and CRD2 (residues 1–120); CRD1 alone or CRD2 alone is insufficient for gD binding. A monoclonal antibody recognizing a discontinuous epitope in CRD1 blocks gD binding, localizing the primary gD contact site to CRD1.\",\n      \"method\": \"Biosensor binding assays, ELISA, virus entry blocking with soluble HVEM truncation mutants and monoclonal antibodies\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal methods (biosensor, ELISA, antibody blocking) with defined domain mapping\",\n      \"pmids\": [\"11119586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Structure-based mutagenesis of the gD-binding site on HVEM identified Y23 (CRD1) as a critical hot-spot residue that protrudes into a crevice on gD; a C37-C19 disulfide bond in CRD1 is essential for gD binding; CRD2 provides structural support for the CRD1 gD-binding site. HVEM-R75A showed enhanced gD binding.\",\n      \"method\": \"Alanine-scanning mutagenesis, gD binding assays, HSV entry assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis with functional entry assay validation\",\n      \"pmids\": [\"12368332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Structure-based mutagenesis of gD defined three critical contact regions at the gD-HVEM interface: (i) residues forming an intermolecular β-sheet with HVEM, (ii) residues contacting HVEM-Y23, and (iii) one gD residue contacting HVEM CRD2. None of the gD mutations prevented nectin-1 binding, demonstrating that the gD binding surfaces for HVEM and nectin-1 are distinct.\",\n      \"method\": \"Site-directed mutagenesis, receptor binding assays, virus entry assay, cell-cell fusion assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis coupled with multiple functional assays\",\n      \"pmids\": [\"12829851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of the BTLA-HVEM complex at 2.8 Å resolution showed that BTLA binds the N-terminal CRD1 of HVEM using a surface that overlaps with the gD-binding site and employs a similar binding motif; BTLA adopts an Ig I-set fold; BTLA is monomeric in solution and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM further defined critical binding residues.\",\n      \"method\": \"X-ray crystallography, light scattering, alanine-scanning mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis plus biophysical stoichiometry measurement\",\n      \"pmids\": [\"16169851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"gD, LT-α, and LIGHT bind to distinct but overlapping sites on HVEM; peptide ligands differentially inhibit gD versus LT-α binding, and binding of one ligand to HVEM alters the receptor conformation, affecting binding of other ligands.\",\n      \"method\": \"Competitive binding assays with recombinant HVEM truncation mutants and peptide inhibitors, ELISA\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding competition assays with defined receptor fragments, single lab\",\n      \"pmids\": [\"11164894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BTLA and HVEM form a cis heterodimeric complex on the surface of naive T cells that inhibits HVEM-dependent NF-κB RelA activation. The cis-BTLA ectodomain competitively blocks trans-engagement of BTLA and CD160 with HVEM. LIGHT can bind the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization in cis. HSV gD forms a cis-complex with HVEM but promotes NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, NF-κB reporter assays, FACS-based binding assays, genetic deletion experiments, pharmacological disruption\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, functional NF-κB assays, genetic and pharmacological approaches in multiple orthogonal experiments\",\n      \"pmids\": [\"19915044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"HVEM engagement of BTLA produces inhibitory signals through SHP-1 and SHP-2 association; conversely, BTLA engagement of HVEM produces proinflammatory signals via NF-κB activation, establishing a bidirectional signaling system between the TNFR and Ig superfamilies.\",\n      \"method\": \"Biochemical signaling assays, co-immunoprecipitation (as reviewed with reference to primary experimental findings)\",\n      \"journal\": \"Annual review of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of experimental findings from multiple labs; SHP-1/SHP-2 recruitment established in primary studies cited\",\n      \"pmids\": [\"20307212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In a T cell transfer colitis model, HVEM expressed by radioresistant innate immune cells (not donor T cells) interacts with BTLA to prevent intestinal inflammation. Loss of HVEM in Rag−/− recipients dramatically accelerated colitis, demonstrating an anti-inflammatory role for HVEM-BTLA signaling in the gut microenvironment.\",\n      \"method\": \"T cell transfer colitis model with HVEM-deficient mice, bone marrow chimeras, in vivo genetic epistasis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular phenotype and epistasis, multiple experimental conditions\",\n      \"pmids\": [\"18519647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HVEM-BTLA signaling provides an inhibitory checkpoint for dendritic cell homeostasis in lymphoid tissue. HVEM- or BTLA-deficient mice have overpopulated CD8α− DC subsets with a specific growth advantage; both DC-intrinsic and microenvironment expression are required. The LTβR pathway provides positive growth signals that are counter-regulated by HVEM-BTLA.\",\n      \"method\": \"Competitive bone marrow chimeric mice, flow cytometry of DC subsets, LTβR agonist antibody treatment, genetic KO\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — competitive repopulation assays and genetic KO with defined cellular phenotype\",\n      \"pmids\": [\"18097025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HVEM promotes the persistence of memory T helper cells (Th1 and Th2) by activating PKB/Akt survival signaling. HVEM-deficient memory CD4 T cells display reduced Akt activity and fail to persist after antigen rechallenge; constitutively active Akt rescues their survival. LIGHT on T cells recapitulates the HVEM effect, suggesting T cell-to-T cell LIGHT-HVEM interactions maintain memory pools.\",\n      \"method\": \"Antigen-specific memory T cell transfer, intracellular signaling assays (Akt phosphorylation), constitutively active Akt rescue, HVEM-KO and LIGHT-KO mice\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic rescue by constitutively active Akt, multiple T cell subsets tested\",\n      \"pmids\": [\"21402741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Loss of HVEM (TNFRSF14) in germinal center B cells leads to cell-autonomous B cell proliferation and drives GC lymphoma development in vivo. HVEM-deficient B cells also induce a tumor-supportive microenvironment with increased TFH recruitment. Disruption of HVEM-BTLA inhibitory cell-cell interactions underlies these effects. The HVEM ectodomain protein (solHVEM) binds BTLA and restores tumor suppression.\",\n      \"method\": \"In vivo mouse lymphoma model, HVEM-KO B cell adoptive transfer, solHVEM protein administration, CAR-T cell engineering\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with multiple mechanistic readouts and protein rescue experiment\",\n      \"pmids\": [\"27693350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HVEM on B cells restrains T follicular helper cell help to germinal center B cells through the BTLA-SHP1 axis: BTLA on T cells recruits SHP1, reduces TCR signaling, and limits preformed CD40L mobilization to the immunological synapse. T cell BTLA deficiency cooperates with B cell Bcl-2 overexpression to drive GC B cell outgrowth, establishing BTLA as a cell-extrinsic suppressor of GC B cell lymphomagenesis.\",\n      \"method\": \"BTLA-deficient T cells, phosphatase (SHP1) signaling assays, imaging of CD40L at the immunological synapse, Bcl-2 transgenic mouse model, in vivo lymphomagenesis model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined mechanistic pathway (SHP1, CD40L mobilization) with genetic and in vivo validation\",\n      \"pmids\": [\"31204070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNFRSF14 (HVEM) expressed on mast cells is engaged by TNFSF14 (LIGHT), enhancing IgE-mediated mast cell signaling and mediator production. In mouse asthma models, TNFRSF14 blockade or genetic deletion of Tnfrsf14 reduces antigen-specific IgE/IgG1, airway hyperreactivity, inflammation, and remodelling. Engraftment of TNFRSF14-deficient mast cells into mast-cell-deficient mice confirmed that MC-expressed TNFRSF14 is required for multiple asthma features.\",\n      \"method\": \"MC-deficient mice reconstituted with TNFRSF14-KO or WT MCs, anti-TNFRSF14 neutralizing antibody, in vitro IgE-mediated signaling assays, in vivo asthma model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-specific reconstitution experiment plus genetic KO plus antibody blockade with defined cellular and molecular phenotype\",\n      \"pmids\": [\"27982078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTLA expressed on DEC205+CD8+CD11c+ dendritic cells promotes induction of extrathymic Foxp3+ regulatory T cells. HVEM engagement on T cells upregulates CD5, which enables Foxp3 expression by allowing T cells to resist cytokine-driven effector differentiation. In the absence of BTLA/HVEM, T cells remain CD5lo and fail to express Foxp3.\",\n      \"method\": \"DC subset-specific BTLA expression analysis, HVEM-KO and BTLA-KO mice, Foxp3 reporter system, CD5 expression assays, tolerance induction experiments\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined mechanistic intermediate (CD5 upregulation), multiple orthogonal readouts\",\n      \"pmids\": [\"27793593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of CD160 bound to HVEM reveals that CD160 adopts a unique Ig fold variant and forms a 1:1 complex with HVEM using a binding interface similar to that of BTLA:HVEM, overlapping on the CRD1 surface of HVEM.\",\n      \"method\": \"X-ray crystallography, solution stoichiometry analysis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of CD160:HVEM complex with biophysical characterization\",\n      \"pmids\": [\"31230945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of HVEM with LIGHT and with BTLA/CD160 define distinct non-overlapping binding surfaces on HVEM: the TNF ligand LIGHT binds one face while BTLA and CD160 bind CRD1. A ternary HVEM-LIGHT-CD160 complex was determined showing simultaneous engagement. HVEM knockin mutant mice selectively recognizing TNF or Ig ligands demonstrated that LIGHT-HVEM interactions are specifically required for intestinal bacterial clearance, while Ig ligand (BTLA/CD160)-HVEM interactions specifically ameliorate liver inflammation.\",\n      \"method\": \"X-ray crystallography (ternary complex), site-directed mutagenesis, knockin mice with ligand-selective HVEM mutants, in vivo infection model, liver inflammation model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure including ternary complex, validated by in vivo knockin muteins with selective loss-of-function phenotypes\",\n      \"pmids\": [\"34709351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Epithelial HVEM, stimulated by LIGHT, promotes survival of intraepithelial T cells (IETs) by upregulating epithelial synthesis of collagen IV (a basement membrane protein), which in turn engages β1 integrins on IETs. This HVEM→collagen IV→β1 integrin axis maintains IET number, patrolling movement, and protective responses to Salmonella enterica.\",\n      \"method\": \"HVEM-KO in intestinal epithelium, RNA-seq of organoids treated with HVEM ligands, intravital microscopy, β1 integrin KO T cells, Salmonella infection model\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including organoid signaling, live imaging, conditional KO, and infection model\",\n      \"pmids\": [\"35905286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTLA on CAR T cells interacts in trans with HVEM expressed on regulatory T cells in the tumor microenvironment, leading to recruitment of tyrosine phosphatases SHP-1 and SHP-2 that inhibit CAR signaling. Deletion of BTLA in CAR T cells improves tumor control and persistence by enhancing CAR signaling and effector function.\",\n      \"method\": \"BTLA-KO in CAR T cells (CRISPR), co-culture with HVEM-expressing Tregs, phosphatase recruitment assays, in vivo lymphoma and solid tumor models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of phosphatase recruitment with genetic KO and in vivo validation\",\n      \"pmids\": [\"38831106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HVEM activates a STAT3 signaling pathway in intestinal epithelial cells (in addition to NF-κB), with STAT3 regulating genes important for host defense and influencing differentiation of Th17 cells and innate lymphoid cells.\",\n      \"method\": \"Signaling assays in epithelial cells, HVEM stimulation experiments (as described in primary studies referenced in the review)\",\n      \"journal\": \"Gut microbes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling pathway identification, but described in a mini-review referencing primary data from a single lab\",\n      \"pmids\": [\"23333859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HSV-1 latency-associated transcript (LAT) upregulates HVEM expression in latently infected neurons, and HVEM-deficient mice show significantly reduced HSV-1 latency and reactivation. Two LAT small noncoding RNAs bind the HVEM promoter, proposing a mechanism whereby LAT increases HVEM expression to promote neuronal survival and immune evasion during latency.\",\n      \"method\": \"Hvem−/− mouse latency model, in vitro LAT expression with HVEM promoter assays, LAT noncoding RNA binding studies\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO model with latency phenotype plus mechanistic promoter binding evidence, single lab\",\n      \"pmids\": [\"24307582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SALM5 (a neuron-specific synaptic adhesion molecule) interacts with HVEM as a functional receptor to suppress CNS inflammation. Anti-SALM5 antibody promoted inflammation in the CNS and aggravated experimental autoimmune encephalomyelitis symptoms, identifying HVEM as a mediator of SALM5-dependent CNS immune privilege.\",\n      \"method\": \"Pulldown/interaction assay, anti-SALM5 monoclonal antibody treatment, EAE mouse model, LPS-induced CNS inflammation\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — novel HVEM binding partner identified with functional in vivo evidence, single lab\",\n      \"pmids\": [\"27152329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HVEM signaling in ILC3 innate lymphoid cells, stimulated by LIGHT, drives protective IFN-γ secretion during Yersinia enterocolitica oral infection. Mice with HVEM-deficient ILC3 show reduced IFN-γ, higher bacterial burdens, and increased mortality; adoptive transfer of WT but not IFN-γ-deficient ILC3 restores protection.\",\n      \"method\": \"Conditional HVEM KO in ILC3, adoptive transfer of IFN-γ-KO ILC3, Yersinia oral infection model\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-specific KO and adoptive transfer rescue experiment with defined mechanistic output (IFN-γ)\",\n      \"pmids\": [\"30092201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HSV-1 gD interaction with HVEM (but not a HVEM-binding-incompetent gD mutant) activates NF-κB-dependent anti-apoptotic signaling in HVEM-expressing cells. Blocking gD-HVEM interaction with specific MAbs or using an HVEM-non-binding gD mutant abolishes protection against Fas-mediated apoptosis, demonstrating that NF-κB survival signaling requires gD-HVEM engagement.\",\n      \"method\": \"MAb blocking of gD-HVEM interaction, gD point mutants unable to bind HVEM, apoptosis assays in HVEM-expressing cells vs. control cells\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — structure-guided loss-of-function (non-binding gD mutant and receptor-specific MAb) with functional apoptosis readout\",\n      \"pmids\": [\"18723002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In T cell reporter systems, co-expression of LIGHT or CD160 (but not BTLA) with HVEM induces strong constitutive HVEM signaling. In the cis-BTLA:HVEM complex, BTLA-mediated inhibitory signaling is dominant and not impaired, while HVEM co-stimulation by trans-ligands is blocked. HVEM antibodies can simultaneously act as checkpoint inhibitors and co-stimulation agonists.\",\n      \"method\": \"T cell reporter systems, primary human T cell stimulation assays, co-expression experiments with HVEM and its ligands\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional reporter assays with primary cells, single lab\",\n      \"pmids\": [\"36081508\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF14/HVEM is a bidirectional signaling receptor that engages structurally distinct ligand classes on separate surfaces: TNF-family members LIGHT and LTα bind one face (activating NF-κB and STAT3 pro-inflammatory/survival pathways via TRAF2/TRAF5), while Ig-superfamily members BTLA and CD160 bind the N-terminal CRD1 (at the same site as HSV gD) to deliver inhibitory signals through SHP-1/SHP-2 recruitment; on naive T cells, HVEM and BTLA form a cis heterodimer that blocks trans-activation and maintains the inhibitory tone, whereas disruption of this complex or loss of HVEM releases B and T cell activation, promotes germinal center responses, and in epithelial cells drives collagen IV production that maintains intraepithelial T cell survival via β1 integrins.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFRSF14 (HVEM) is a bidirectional signaling hub at the interface of the TNF receptor and immunoglobulin superfamilies, integrating pro-inflammatory, survival, and inhibitory signals to regulate lymphocyte activation, memory, tolerance, and mucosal immunity. Its CRD1 domain engages Ig-superfamily ligands BTLA and CD160 (and HSV glycoprotein D) to deliver inhibitory signals via SHP-1/SHP-2 recruitment on the opposing cell, while a distinct surface binds TNF-family ligands LIGHT and LTα to activate NF-κB (through TRAF2/TRAF5), STAT3, and Akt survival pathways [PMID:9153189, PMID:34709351, PMID:20307212, PMID:21402741]. On naive T cells, HVEM and BTLA form a cis-complex that competitively blocks trans-engagement, maintaining inhibitory tone; disruption of this complex releases B and T cell activation and, in germinal center B cells, promotes lymphomagenesis driven by unchecked TFH help [PMID:19915044, PMID:27693350, PMID:31204070]. In mucosal tissues, LIGHT–HVEM signaling on ILC3 drives protective IFN-γ during enteric infection, while epithelial HVEM stimulates collagen IV production that sustains intraepithelial T cell survival through β1 integrins [PMID:30092201, PMID:35905286].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of HVEM as the entry receptor for HSV via direct binding of glycoprotein D established that a TNF receptor family member could serve as a viral receptor, opening investigation of its ligand repertoire.\",\n      \"evidence\": \"Recombinant protein binding assays, gel filtration, and CHO cell infection assays\",\n      \"pmids\": [\"9223502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological (non-viral) ligands were unknown\", \"Signaling consequences of gD engagement were uncharacterized\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that HVEM signals through TRAF2 and TRAF5 to activate NF-κB revealed that HVEM functions as a classical TNFR-family signaling receptor, not merely a viral entry factor.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, NF-κB reporter assay with domain mapping\",\n      \"pmids\": [\"9153189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of endogenous activating ligands was unknown\", \"Downstream transcriptional targets of HVEM-NF-κB not defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Competitive binding studies showed that gD, LTα, and LIGHT occupy distinct but overlapping sites on HVEM, establishing that HVEM is a multi-ligand receptor capable of integrating different inputs.\",\n      \"evidence\": \"Competitive binding assays with recombinant HVEM truncation mutants and peptide inhibitors\",\n      \"pmids\": [\"11164894\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for distinct binding faces not resolved\", \"Functional consequence of simultaneous ligand engagement unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Crystal structures of gD alone and in complex with HVEM, combined with domain mapping, localized the gD contact to CRD1 and revealed a conformational change mechanism relevant to viral entry.\",\n      \"evidence\": \"X-ray crystallography at atomic resolution; biosensor binding and antibody blocking with HVEM truncation mutants\",\n      \"pmids\": [\"11511370\", \"11119586\", \"12368332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CRD1 also served as the binding site for endogenous Ig-superfamily ligands was unknown\", \"Structural basis for LIGHT/LTα binding not yet determined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The crystal structure of the BTLA–HVEM complex revealed that an Ig-superfamily inhibitory receptor binds CRD1 of a TNF receptor, using a surface overlapping with gD, establishing an unprecedented cross-superfamily signaling paradigm.\",\n      \"evidence\": \"X-ray crystallography at 2.8 Å, light scattering, alanine-scanning mutagenesis\",\n      \"pmids\": [\"16169851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BTLA inhibitory signaling was transduced upon HVEM engagement was incompletely defined\", \"Whether CD160 shared this binding mode was unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"In vivo genetic studies demonstrated that HVEM–BTLA signaling functions as an inhibitory checkpoint controlling dendritic cell homeostasis and preventing intestinal inflammation, establishing HVEM's physiological role as a negative regulator beyond T cells.\",\n      \"evidence\": \"HVEM-KO and BTLA-KO mice, competitive bone marrow chimeras, T cell transfer colitis model\",\n      \"pmids\": [\"18519647\", \"18097025\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions of HVEM in epithelium vs. immune compartment were not separated\", \"STAT3 pathway involvement not yet established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"gD–HVEM engagement was shown to activate NF-κB-dependent anti-apoptotic signaling, demonstrating that HSV exploits HVEM survival signaling during infection.\",\n      \"evidence\": \"Blocking MAbs, non-binding gD mutants, Fas-mediated apoptosis assays in HVEM-expressing cells\",\n      \"pmids\": [\"18723002\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this survival pathway operates during latency was unresolved\", \"Downstream NF-κB target genes not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that BTLA and HVEM form a cis-complex on naive T cells that blocks trans-activation resolved how inhibitory tone is maintained at steady state and explained why HVEM loss leads to immune activation.\",\n      \"evidence\": \"Co-immunoprecipitation, NF-κB reporter assays, FACS-based binding, genetic deletion in T cells\",\n      \"pmids\": [\"19915044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism preventing HVEM oligomerization in cis not fully resolved\", \"How the cis-complex is disrupted during activation was not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Characterization of HVEM–BTLA as a bidirectional signaling axis — BTLA delivers SHP-1/SHP-2 inhibitory signals while HVEM receives NF-κB-activating signals — unified the co-stimulatory and co-inhibitory functions into a single molecular interaction.\",\n      \"evidence\": \"Biochemical signaling assays, co-immunoprecipitation (synthesized from multiple primary studies)\",\n      \"pmids\": [\"20307212\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of SHP-1 vs. SHP-2 in different cell types not delineated\", \"Quantitative signaling thresholds not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"HVEM was shown to promote memory T cell persistence through Akt survival signaling triggered by LIGHT, identifying a non-redundant role for HVEM in adaptive immune memory maintenance.\",\n      \"evidence\": \"HVEM-KO and LIGHT-KO memory CD4 T cell transfers, Akt phosphorylation assays, constitutively active Akt rescue\",\n      \"pmids\": [\"21402741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Akt activation is TRAF-dependent or uses a distinct adaptor was unknown\", \"Role in CD8 memory maintenance not fully tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"HSV-1 latency-associated transcript was found to upregulate HVEM expression in neurons, and HVEM-deficient mice showed reduced latency and reactivation, revealing that HSV co-opts HVEM signaling for long-term persistence.\",\n      \"evidence\": \"Hvem−/− mouse latency model, LAT noncoding RNA promoter-binding studies\",\n      \"pmids\": [\"24307582\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LAT–HVEM promoter interaction not validated by independent lab\", \"Downstream neuronal survival pathway not fully delineated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Loss of HVEM in germinal center B cells was shown to drive cell-autonomous proliferation and lymphomagenesis; soluble HVEM ectodomain restored BTLA-dependent tumor suppression, establishing HVEM as a tumor suppressor in GC B cell lymphoma.\",\n      \"evidence\": \"In vivo mouse lymphoma model, HVEM-KO B cell adoptive transfer, solHVEM protein rescue, CAR-T engineering\",\n      \"pmids\": [\"27693350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether solHVEM achieves durable suppression in established tumors was not tested\", \"Downstream transcriptional program in HVEM-deficient GC B cells not characterized\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Multiple tissue-specific roles of HVEM were simultaneously uncovered: BTLA-expressing DCs use HVEM engagement to upregulate CD5 and induce Foxp3+ regulatory T cells; HVEM on mast cells mediates LIGHT-driven IgE signaling and asthma pathology; and SALM5 was identified as a neuronal HVEM ligand suppressing CNS inflammation.\",\n      \"evidence\": \"DC subset analysis in HVEM/BTLA-KO mice with Foxp3 reporters; mast cell reconstitution in MC-deficient mice with TNFRSF14-KO MCs; pulldown and EAE model for SALM5\",\n      \"pmids\": [\"27793593\", \"27982078\", \"27152329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SALM5–HVEM interaction awaits structural validation and independent confirmation\", \"Mast cell HVEM signaling intermediates beyond NF-κB not defined\", \"Whether CD5 upregulation is a direct HVEM transcriptional target unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"HVEM signaling in ILC3 was shown to drive protective IFN-γ production during enteric bacterial infection, extending HVEM's mucosal defense role to innate lymphoid cells.\",\n      \"evidence\": \"Conditional HVEM KO in ILC3, adoptive transfer of IFN-γ-KO ILC3, Yersinia oral infection model\",\n      \"pmids\": [\"30092201\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates linking HVEM to IFN-γ transcription in ILC3 not identified\", \"Whether LIGHT is the sole activating ligand for ILC3-HVEM in vivo not confirmed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structure of CD160–HVEM confirmed that CD160 shares the CRD1 binding surface with BTLA, and mechanistic studies showed that BTLA on T cells recruits SHP1 to suppress TCR signaling and CD40L mobilization, establishing the molecular basis for HVEM-dependent GC B cell lymphoma suppression.\",\n      \"evidence\": \"X-ray crystallography of CD160:HVEM; BTLA-KO T cells with SHP1 signaling and CD40L imaging in Bcl-2 transgenic lymphomagenesis model\",\n      \"pmids\": [\"31230945\", \"31204070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD160 delivers inhibitory or activating signals through HVEM in vivo not fully resolved\", \"Relative contributions of SHP1 vs SHP2 to BTLA-mediated suppression of TCR signaling not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Crystal structures of HVEM with LIGHT and a ternary HVEM–LIGHT–CD160 complex definitively showed that TNF and Ig ligands bind non-overlapping surfaces, enabling simultaneous engagement; ligand-selective HVEM knockin mice proved that LIGHT–HVEM drives intestinal bacterial clearance while BTLA/CD160–HVEM ameliorates liver inflammation.\",\n      \"evidence\": \"X-ray crystallography including ternary complex, knockin mice with ligand-selective HVEM mutations, infection and inflammation models\",\n      \"pmids\": [\"34709351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How simultaneous ternary engagement alters net signaling output quantitatively is unclear\", \"Whether the ternary complex forms physiologically in specific tissues not demonstrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Epithelial HVEM was shown to sustain intraepithelial T cells by a previously unrecognized mechanism: LIGHT-HVEM signaling induces epithelial collagen IV, which engages β1 integrins on IETs to promote survival and motility.\",\n      \"evidence\": \"Epithelial HVEM conditional KO, organoid RNA-seq, intravital microscopy, β1 integrin KO T cells, Salmonella infection model\",\n      \"pmids\": [\"35905286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling pathway from HVEM to collagen IV transcription in epithelial cells not fully mapped\", \"Whether this axis operates outside the gut epithelium unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"HVEM on regulatory T cells in the tumor microenvironment was identified as a functional ligand that engages BTLA on CAR T cells, recruiting SHP-1/SHP-2 to suppress CAR signaling; BTLA deletion in CAR T cells enhanced anti-tumor efficacy, validating the HVEM–BTLA axis as a therapeutic target in adoptive cell therapy.\",\n      \"evidence\": \"CRISPR BTLA-KO in CAR T cells, co-culture with HVEM+ Tregs, phosphatase recruitment assays, in vivo lymphoma and solid tumor models\",\n      \"pmids\": [\"38831106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HVEM on other TME cell types contributes to CAR T suppression not addressed\", \"Long-term safety of BTLA-deleted CAR T cells not evaluated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include the signaling intermediates linking HVEM to STAT3 and Akt in different cell types, how the cis-BTLA:HVEM complex is physiologically disrupted during activation, the structural basis for SALM5–HVEM interaction, and whether ternary HVEM–LIGHT–CD160 complexes form in vivo and alter net signaling output.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Adaptor proteins linking HVEM to Akt not identified\", \"Mechanism of cis-to-trans switch during T cell activation undefined\", \"SALM5–HVEM structural and biophysical characterization absent\", \"Physiological relevance of ternary complex in specific tissues not demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 7, 8, 9, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 9, 13, 14, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 8, 17, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 13, 14, 15, 16, 20, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 8, 9, 12, 21, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 13, 22]}\n    ],\n    \"complexes\": [\n      \"cis-BTLA:HVEM complex\"\n    ],\n    \"partners\": [\n      \"BTLA\",\n      \"CD160\",\n      \"TNFSF14\",\n      \"LTA\",\n      \"TRAF2\",\n      \"TRAF5\",\n      \"PTPN6\",\n      \"PTPN11\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}